Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice

Hang Sun\textsuperscript{1}\textsuperscript{†}, Xingchun Wang\textsuperscript{1}\textsuperscript{†}, Jiaqi Chen\textsuperscript{2}, Kexiu Song\textsuperscript{1}, Aaron M. Gusdon\textsuperscript{3}, Liang Li\textsuperscript{1}, Le Bu\textsuperscript{1} and Shen Qu\textsuperscript{1}\* 

Abstract

Background: Melatonin can regulate lipid metabolism, increase insulin sensitivity, regulate glucose metabolism and reduce body weight. This study is aimed to determine the effects and mechanism of action of melatonin on non-alcoholic fatty liver disease (NAFLD) in high-fat-diet (HFD) induced obese mice.

Methods: NAFLD was induced by HFD in C57BL/6 mice. A total of 24 mice were randomly assigned to 4 groups. Groups A and B were fed with HFD for 36 weeks while groups C and D were fed with a regular diet (RD). During the last 12 weeks, Groups A and C were treated with 10 mg/kg melatonin while Groups B and D were treated with water in the same volume by intragastric administration. Body and liver weight, blood glucose, serum transaminases and lipid levels, and markers of hepatic inflammation were measured. Histological analyses were also performed on liver tissue.

Results: After 12 weeks of treatment with melatonin, body weights (Group A: before 53.11 ± 0.72 vs after 12w treatment 39.48 ± 0.74) and liver weights (A 1.93 ± 0.09 g vs B 2.92 ± 0.19 g vs C 1.48 ± 0.09 g vs D 1.49 ± 0.10 g), fasting plasma glucose, alanine transaminase (A 24.33 ± 11.90 IU/L vs B 60.80 ± 10.18 IU/L vs C 13.01 ± 3.49 IU/L vs D 16.62 ± 2.00 IU/L), and low-density cholesterol (A 0.24 ± 0.06 mmol/L vs B 1.57 ± 0.10 mmol/L vs C 0.28 ± 0.06 mmol/L vs D 0.29 ± 0.03 mmol/L) were significantly decreased in HFD mice. HFD fed mice treated with melatonin showed significantly less liver steatosis. Treatment of HFD fed mice with melatonin led to a significant decrease in the expression of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 measured using quantitative real-time polymerase chain reaction (qRT-PCR). HFD fed mice demonstrated increased phosphorylation of P38 and JNK1/2, which was reduced by melatonin treatment.

Conclusions: The study concluded that melatonin could improve NAFLD by decreasing body weight and reduce inflammation in HFD induced obese mice by modulating the MAPK-JNK/P38 signaling pathway.

Keywords: Melatonin, NAFLD, Obesity, Inflammation, MAPK

Background

Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in hepatocytes and precedes hepatic steatosis and occurs in the absence of alcohol consumption [1]. NAFLD is a growing public health concern worldwide because of its high morbidity and its association with hyperlipidemia, diabetes, and obesity [1, 2]. Simple steatosis occurs early in the course of NAFLD and progresses to nonalcoholic steatohepatitis (NASH) and finally to liver cirrhosis [3]. Obesity is an important risk factor driving the development of NAFLD [4]. A high-fat-diet (HFD) may act as the 'first hit' leading to NAFLD while inflammation likely serves as a 'second hit' driving progression from NAFLD to NASH [5]. Currently, treatment for NAFLD is mainly aimed at modifying risk factors, but there are no therapies directly targeting underlying liver pathology [6].

Melatonin is a hormone secreted by the pineal gland. The synthesis and secretion of melatonin are regulated by light intensity [7]. It has been demonstrated that...
Melatonin has multiple biological effects and acts as an anti-oxidant [8, 9]. It has anti-inflammatory properties [10, 11], regulates circadian rhythms [12] and immunity [13]. It also has anti-neoplastic effects [14]. Recent research has also found that melatonin can regulate lipid metabolism [15], increase insulin sensitivity [16], regulate glucose metabolism [17], and reduce body weight [18]. It was found that melatonin could improve HFD-induced NAFLD and attenuate oxidative stress [19]. Stacchiotti et al. also found that melatonin treatment could improve hepatic macrosteatosis in NAFLD in ob/ob mice [20]. However, the underlying mechanisms remain unclear. This study was designed to investigate the effect of melatonin on HFD induced NAFLD and explore the underlying mechanism.

**Methods**

**Experimental design**

24 male C57BL/6 mice (6 weeks old, 21.32 ± 0.85 g) were purchased from Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China). The mice were housed in a clean room maintained at 24 ± 2 °C under a 12 h:12 h light:dark cycle, with free access to food and water. All animal experiments were approved by the Animal Care and Use Committee of Tongji University with the Ethics Protocol number Q520140305. Mice were randomly assigned to 4 groups. Group A (n = 6) and Group B (n = 6) were fed with HFD for 36 weeks, while Group C and Group D were fed with regular diet (RD). After 24 weeks, Group A and Group C received 10 mg/kg melatonin by intragastric administration while Group B and Group D received double-distilled water in same volume by intragastric administration consistently between 7 pm and 8 pm for 12 weeks, according to previous studies [19, 21–23]. HFD and RD were purchased from Meidisen Biomedical Company (Jiangsu, China). The diets follow the AIN93 recommendations. The high fat diet (research diet D12492) contains 60% calories from fat, 20% from carbohydrates and 20% from proteins. The regular diet (research diet D12450B) contains 10% calories from fat, 70% from carbohydrates and 20% from proteins. Melatonin was purchased from Sigma Aldrich Chemical Co. (St. Louis, MO, USA), dissolved in water.

**Body weight and liver weight evaluation**

Body weight was measured every 4 weeks consistently between 7 pm and 8 pm. Liver weight was measured after sacrifice.

**Blood glucose, transaminase and lipid levels**

Blood glucose was determined after tail-snipping and measured using a glucose test strip reader. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), triglycerides (TG), low-density cholesterol (LDL-C) and high-density cholesterol (HDL-C) were measured spectrophotometrically according to the instructions (NJJCBIO, Jiangsu, China).

**Histological analyses**

Paraffin sections of liver, 4 μm thick, were processed for hematoxylin-eosin (HE) staining. Frozen sections of liver, 8 μm thick, were processed routinely for Oil Red O staining.

Volume density (Vv) of hepatic steatosis was analyzed using the software Image Pro Plus, version 7.01 for Windows (Media Cybernetics, Silver Springs, MD, USA) as described [24].

**Real-time reverse-transcriptase polymerase chain reaction (qRT–PCR)**

Total mRNA from the mouse liver was isolated using the Trizol reagent from Invitrogen (Carlsbad, CA). Two micrograms of total RNA were used for cDNA synthesis using an RNasea kit (QIAGEN) according to the manufacturer’s instructions. Quantitative real-time SYBR Green quantitative RT-PCR was performed using a 7900HT real-time PCR system (ABI, CA, USA) to determine the expression of target genes according to the instructions of the SYBR Premix EX Taq (TaKaRa Biotechnology, China). Data were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as an endogenous control and analyzed using the ΔΔCt method. Primer sequences are provided in Table 1.

| Primer Name | Sequence (5'-3') Length |
|-------------|-------------------------|
| TNF-a       | CCCTCACACTCAGATCATCTTCT 23 |
| IL-1b       | GCTACTGTTGGGTCGAC 19     |
| IL-6        | ATCTTTGGGTGGGTCGAC 21    |
| IL-10       | TAGTTTCTCTCCCAATTC 23    |
| JNK         | ATCTTTGGGTGGGTCGAC 21    |
| IKKβ        | AGAGACTAATGGTTGG 20     |
| GAPDH       | AGGGTGTGCTAGTTGGAGAT 21  |

**Table 1** Primer sequence of Real-time PCR
Western blotting
Expression of total c-Jun N-terminal kinases (JNK), phospho-JNK (p-JNK), total P38 and phospho-P38 (p-P38) in liver were measured by Western blotting as described [25]. Proteins were separated on 12.5% SDS-PAGE gels and transferred onto nitrocellulose membranes. Antibodies were purchased from Cell Signaling Technology (USA). P38, p-P38, JNK, p-JNK expression was analyzed using a rabbit monoclonal antibody (1:1000) primary antibody, and a rabbit-anti-mouse IgG-HRP (1:1000) secondary antibody. GAPDH (1:1000 dilution for the primary antibody and 1:1000 dilution for the secondary antibody was used as an endogenous control. Western blot bands were scanned and quantified by densitometry analysis using an image analyzer Quantity One System (Odyssey, USA).

Statistical evaluation
Statistical analyses were performed using SPSS 21.0 software (Chicago, IL) and GraphPad Prism software (GraphPad Software Inc). Data were presented as mean values ± standard errors. The ANOVA test was used to determine differences between groups comparing the internal variability of group with the variability among all experimental groups. Multiple comparisons between the groups were performed using S-N-K method as a post-hoc test. P values <0.05 were considered statistically significant. All assays were performed in triplicate.

Results
In this study, HFD mice treated with melatonin were compared with HFD mice treated with water, and with lean mice being either treated or not treated with melatonin. Lean mice that were treated or not treated with melatonin had similar weights, glucose metabolism, lipid metabolism, and levels of inflammatory markers, so both groups are referred to as controls.

Body weight and liver mass
As shown in Fig. 1A, HFD increased body weight and liver mass compared with RD. [at 24w: (A) 53.11 ± 0.72 vs (B) 53.30 ± 0.60 vs (C) 37.25 ± 0.40 vs (D) 37.50 ± 0.39 g]. The average body weight of high fat diet fed mice is ~42.4% more than the regular diet fed mice. Administration of melatonin significantly reduced both body weight by ~30.2% less than the HFD mice [at36w: (A) 39.48 ± 0.74 vs (B) 56.56 ± 0.62 vs (C) 38.18 ± 0.45 vs (D) 38.01 ± 0.44 g]. Livers were removed upon sacrifice and liver mass was measured. As shown in Fig. 1B, the liver mass of melatonin treated mice is ~ 33.9% less than the HFD mice [(A) 1.93 ± 0.09 vs (B) 2.92 ± 0.19 vs (C) 1.48 ± 0.09 vs (D) 1.49 ± 0.10 g] (p < 0.01 between A and B).

Glucose and lipid metabolism
As shown in Table 2 and Fig. 2, after ANOVA test performed among four groups and independent sample T-test used between two groups as a post-hoc test with ANOVA test. It was found that melatonin treatment significantly reduced fasting plasma glucose (FPG) (Fig. 2a), ALT (Fig. 2b), and LDL (Fig. 2c) in Group A compared with Group B fed with HFD only, p < 0.01 between A and B.

Histological analyses of liver
HFD fed mice developed liver steatosis. By contrast, HFD mice treated with melatonin showed a significantly less liver steatosis (Fig. 3).

Inflammatory
The mRNA levels of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), IL-1β, and IL-6 significantly increased in the HFD group compared with RD fed mice, and HFD mice treated with melatonin demonstrated significantly lower expression of TNF-α,
IL-1β, and IL-6 (Fig. 4). IL-10 and IKK-β were not significantly different.

Furthermore, we evaluated the expression of P38 and c-Jun N-terminal kinases (JNK) 1/2 in liver by Western blotting (Fig. 5). HFD increased phosphorylated levels of P38 and JNK1/2, which was reversed by treatment with melatonin.

Discussion
Numerous studies have demonstrated that melatonin treatment reduces body weight in both animal models and human [26–29]. A recent study demonstrated that melatonin has effects on inflammation, fat deposition, and energy metabolism in ob/ob mice [30]. In this study, we found that melatonin treatment for 12 weeks significantly decreased body weight and liver weight in HFD mice. Melatonin was also found to regulate glucose metabolism. There are two membrane receptors of melatonin called MT1 and MT2, which are G-protein-coupled receptors, in the periphery [31]. Both receptors are expressed in the islet of Langerhans and are involved in the regulation of glucagon secretion from α-cells and insulin secretion from β-cells [16, 32]. Several studies indicate that activation of MT1 or MT2 leads to a reduction in second messenger 3',5'-cyclic adenosine monophosphate (cAMP) or 3',5'-cyclic guanosine monophosphate (cGMP) accompanied by reduced insulin secretion [33, 34]. Consistent with this mechanism, we found that melatonin treatment significantly reduced HFD induced elevations in blood glucose.

Early experiments showed that treatment with melatonin can improve dyslipidemia [15]. In patients with NAFLD, treatment with melatonin (2-5 mg/day) for 14 months significantly reduced levels of triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) compared with controls treated with Essentiale [35]. Treatment with melatonin for two weeks significantly reduced free fatty acids (FFA) compared with placebo in cigarette smokers [36]. A study assessing aluminium-induced toxicity in a rat model found that melatonin protected against toxic dyslipidemia by alleviating the aluminum induced increases in total cholesterol (TC), LDL-C, TG, oxidized LDL, and apolipoprotein B100 (apoB100) [37]. Pan et al [38] found that melatonin

Table 2 Effects of melatonin on fasting plasma glucose, serum transaminase, and lipid levels

|                  | Group A    | Group B    | Group C    | Group D    |
|------------------|------------|------------|------------|------------|
| FPG, mmol/L      | 5.03 ± 0.38* | 8.45 ± 0.35# | 4.71 ± 0.29 | 4.85 ± 0.33 |
| HDL, mmol/L      | 1.71 ± 0.53 | 1.51 ± 0.39 | 2.05 ± 0.43 | 1.99 ± 0.37 |
| LDL, mmol/L      | 0.24 ± 0.06* | 1.57 ± 0.10# | 0.28 ± 0.06 | 0.29 ± 0.03 |
| TG, mmol/L       | 1.11 ± 0.35 | 1.06 ± 0.24 | 1.18 ± 0.15 | 1.24 ± 0.18 |
| AST, IU/L        | 20.31 ± 4.41 | 20.01 ± 1.20 | 14.98 ± 4.39 | 13.35 ± 1.57 |
| ALT, IU/L        | 24.33 ± 11.90* | 60.80 ± 10.18# | 13.01 ± 3.49 | 16.62 ± 2.00 |

Group A: HFD + MLT, Group B: HFD, Group C: RD + MLT, Group D: RD. FPG fasting plasma glucose, HDL high-density cholesterol, LDL low-density cholesterol, TG Triglycerides, AST aspartate aminotransferase and ALT Alanine aminotransferase. *P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D.

Fig. 2 Effect of melatonin on fasting plasma glucose, serum transaminase, and lipid levels. (a) Fasting plasma glucose (FPG, mmol/L). *P < 0.05 vs group A. (b) Alanine aminotransferase (ALT, IU/L) and aspartate aminotransferase (AST, IU/L). *P < 0.05 vs other 3 groups. (c) Triglycerides (TG, mmol/L), low-density cholesterol (LDL-C, mmol/L) and high-density cholesterol (HDL-C, mmol/L). *P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D.
ameliorates NAFLD by lowering serum AST, ALT, liver total cholesterol, and triglycerides in high-fat diet fed rats. Consistently, in this study, we have demonstrated that melatonin administration decreases serum LDL and ALT and reduces the degree of hepatocyte steatosis.

To explore the possible mechanism of melatonin’s beneficial effects on NAFLD, we measured mRNA levels of pro-inflammatory markers and the active levels of mitogen-activated protein kinase (MAPK) signaling. Inflammation contributes to the progression of NAFLD to NASH [5]. We found that melatonin treatment significantly reduced the mRNA level of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, which were increased in HFD fed mice. The expression of total JNK1/2 and P38 were similar in four groups, but the phosphorylated levels of P38 and JNK1/2 were increased in HFD mice compared with RD fed mice. The activation of the JNK1/2 and P38 signaling molecules by HFD was reduced by melatonin administration. There are many signaling pathways involved in the progression of hepatic steatosis with numerous interactions among the different pathways. The MAPK signaling pathway is involved in the regulation of inflammation and fatty acid metabolism [39, 40]. HFD leads to inflammation and weight gain, and melatonin treatment could alleviate the inflammation as well as obesity caused by HFD. RD did not lead to any disorders, so melatonin supplemental in RD fed mice would have limited effects on changes in

![Fig. 3 Histological analyses of liver steatosis. Representative images (400×) of H&E-stained (Upper) and Oil Red O-stained (Lower) liver sections from (a) HFD with melatonin, (b) HFD, (c) RD with melatonin, and (d) RD.](image)

![Fig. 4 Quantification of pro-inflammatory cytokines. qRT-PCR was conducted in order to analyze the expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), c-Jun N-terminal kinases (JNK), and inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β). *P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D.](image)
weight, glucose metabolism, lipid metabolism, and inflammation status. Taken together, our data indicate that melatonin affects the signaling pathways leading to elevated inflammatory responses induced by HFD. We hypothesize that the decreased levels of inflammation after melatonin treatment could improve liver pathology in NAFLD and inhibits progression to NASH.

This study had several limitations. Firstly, we did not record the food intake of experimental animals, which was one of the limitations of the study. However, a previous study showed that melatonin treatment could reduce body weight without affecting food intake [41]. And another study demonstrated that ob/ob mice with melatonin administration consumed more food than their genotype counterparts without gaining weight [26]. The effect of melatonin on food intake does need to be further explored.

Reduced body mass could lead to a reduction of adiposity and ectopic accumulation of fat, thus reducing hepatic steatosis. A reduction of steatosis, in turn, down-regulates inflammatory markers. In our study, body mass decreased with melatonin treatment, which could be explained possibly by the melatonin effects on body mass, or other beneficial effects. However, we would also consider the therapeutic effect of melatonin on NAFLD as a result of both anti-inflammation and anti-obesity functions. Previous studies have shown the anti-inflammatory properties of melatonin [10, 11]. In our study, we also found the anti-inflammatory effects on mice fed with HFD, but not on mice fed with regular diet. During the initiation and progression of hepatic steatosis. The dysregulation of lipid metabolism is frequently associated with an inflammatory condition [42], and the elevated inflammatory status plays an important role in the development of insulin resistance, which in turn further promotes ectopic fat accumulation in the liver, forming a vicious cycle [43].

Conclusion
This study concluded that the treatment with melatonin could decrease body weight and ameliorate liver pathology due to NAFLD in HFD induced obese mice. Melatonin likely decrease inflammation via the MAPK-JNK/P38 signaling pathway.

Abbreviations
NAFLD: Non-alcoholic fatty liver disease; HFD: High-fat-diet; RD: Regular diet; qRT-PCR: Quantitative real-time polymerase chain reaction; NASH: Nonalcoholic steatohepatitis; ALT: Alanine aminotransferase; AST: aspartate aminotransferase; TG: Triglycerides; LDL-C: Low-density cholesterol; HDL-C: High-density cholesterol; HE: Hematoxylin-eosin; JNK: c-Jun N-terminal kinases; p-JNK: phospho-JNK; p-P38: total P38 and phospho-P38; cAMP: 3′,5′-cyclic adenosine monophosphate; cGMP: 3′,5′-cyclic guano-sine monophosphate; FFA: Free fatty acids; apoB100: apolipoprotein B100; MAPK: Mitogen-activated protein kinase

Acknowledgements
Not applicable.

Funding
This article received support from the National Natural Science Foundation of China (NSFC) (grant numbers 81550110260 and 81570782).

Availability of data and materials
The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SQ designed the study. HS performed the animal experiment, collected the data, and drafted the manuscript. WXC assisted the manuscript revision and language editing. JC performed the statistical analysis and histological analyses. KS performed the molecular studies. AMG revised the manuscript. LL and LB participated in the data collection, statistical analysis and participated in the design of the study, literature search and the preparation of manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.
Ethics approval and consent to participate
All animal experiments were approved by the Animal Care and Use Committee of Tongji University.

Endnotes
Not applicable.

Author details
1Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
2Nanjing Medical University, Nanjing, Jiangsu 210029, China. 3Department of Neurology, Weill Cornell Medical College, New York, NY 10065, USA.

Received: 13 July 2016 Accepted: 10 November 2016
Published online: 23 November 2016

References
1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2013;310(22):2263–73.
2. Williams CD, Stengel J, Asike MJ, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.
3. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128(5):837–47.
4. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519–23.
5. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–5.
6. Marchesini G, Petta S, Dalle Grave R, Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. 2015. Hepatology.
7. Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem. 2006;43(Pt 5):S44–53.
8. Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with plasma leptin and insulin independent of food intake and total body fat. Endocrinology. 2000;141(2):487–97.
9. Rasmussen DD, Boldt BM, Wilkinson CW, Yllon SM, Matsumoto AM. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat.
10. Melatonin Lulling Th17 cells to sleep. Cell. 2015;162(6):1212–23.
11. Lee JS, Cua DJ. Melatonin. Proc Jpn Acad Ser B Phys Biol. 2007;83(2):154–60.
12. Lewis NJ, Zvonic S, Saini S, Schernthaner GH, Schernthaner GH. Melatonin: a potential intervention for hepatic steatosis in liver biopsies. Virchows Arch. 2011;459(5):477–85.
13. Guidon AM, Fernandez-Buena GA, Winckelmans S, Fernandez J, Chen J, Mathews CE. Respiration and substrate transport rates as well as reactive oxygen species production distinguish mitochondria from brain and liver. BMC Biochem. 2015;16:22.
14. Wolden-Hanson T, Mitton DR, McCants RL, Yellow SM, Wilkinson CW, Matsumoto AM, Rasmussen DD. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat.
15. Hatzis G, Ziakas P, Kavantzas N, Triantafyllou A, Sigalas P, Andreadou I, Ioannidis K, Chatzis S, Filis K, Papalampros A, Sigala F. Melatonin attenuates melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(1):11–20.
16. Vriend J, Reiter RJ, Gonzalez-Gallego J. A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives. J Pineal Res. 2013;54(1):1–14.
17. Borges Lda S, Derrmgo A, da Silva Junior EP, Weimann E, Lambertucci RH, Hatanaka E. Melatonin decreases muscular oxidative stress and inflammation induced by strenuous exercise and stimulates growth factor synthesis. J Pineal Res. 2015;58(2):166–72.
18. Vriend J, Reiter RJ. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res. 2015;58(1):1–11.
19. Lee JS, Cua DJ. Melatonin Lulling Th17 cells to sleep. Cell. 2015;162(6):1212–23.
20. Di Bella G, Masofa F, Gualano L, Di Bella L. Melatonin antifibrosis effects: review. Int J Mol Sci. 2013;14(2):2410–30.
21. Sun H, Huang FF, Ou S. Melatonin: a potential intervention for hepatic steatosis. Lipids Health Dis. 2015;14:75.
22. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: – conditional pro-oxidant actions. J Pineal Res. 2014;57(2):131–3.
23. Eckel RH, Depner CM, Pereaut L, Markwald RR, Smith MR, McHill AW, Higgins J, Melanson EL, Wright Jr KP. Morning circadian misalignment during short sleep duration impacts insulin sensitivity. Curr Biol. 2015;25(22):3004–12.
24. Chojnacki C, Walecka-Kapica E, Klupinska G, Pawlowlczik M, Bonska A, Chojnacki J. Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women. J Physiol Pharmacol. 2015;66(5):65–71.
25. Favero G, Stacchiotti A, Castrellati S, Bonfinomi F, Albanez M, Rezani R, Rodella LF. Melatonin reduces obesity and restores adipokine patterns and metabolism in obese (ob/ob) mice. Nutr Res. 2015;35(10):891–900.
26. Leo J, Leary PA, Fierro J, Capp et al. Melatonin ameliorates nonalcoholic fatty liver disease in mice. J Pineal Res. 2015;59(4):403–11.
27. Legros C, Devavry S, Tessier C, Delagrange P, Ouvry C, Boutilier C, Nogues J, Nojean O. Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol. 2014;171(11):186–201.
28. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol. 2002;191(2):157–66.
29. MacKenzie RS, Melan MA, Passey DK, Witt-Endyber PA. Dual coupling of MT1 and MT2 melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol. 2002;63(4):587–95.
30. Sartori C, Dessens P, Mathieu C, Monney A, Bloch J, Nicod P, Scherer U, Duplain H. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat-fed insulin-resistant mice. Endocrinology. 2005;156(10):5311–7.
31. Celinski K, Konturek PC, Stolmka M, Cichoz-Lach H, Brzozowski T, Konturek SJ, Korolczuk A. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease—14 months follow up. J Physiol Pharmacol. 2014;65(1):75–82.
32. Wang Z, Li, Wang J, Lu C, Ren M, Han W, Liu C. The protective effect of melatonin on smoke-induced vascular injury in rats and humans: a randomized controlled trial. J Pineal Res. 2016;60(2):217–27.
33. Allagui MS, Hachani R, Saidi S, Feriani A, Murat JC, Kacem K, El Feki A. Pleiotropic protective roles of melatonin against aluminium-induced toxicity in rats. Gen Physiol Pharmacol. 2015;34(4):415–24.
34. Pan M, Song YL, Xu JM, Gan HZ. Melatonin ameliorates nonalcoholic fatty liver injury induced by high-fat diet in rats. J Pineal Res. 2006;41(1):70–9.
35. Hayakawa R, Hayakawa T, Takeda K, Ichijo H. Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(8):434–53.
Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis. Mol Cell Biol. 2015;35(1):26–40.

41. de Luxan-Delgado, Potes BY, Rubio-Gonzalez A, Caballero B, Solano JJ, Fernandez-Fernandez M, Bermudez M, Rodrigues Moreira Guimaraes M, Vega-Naredo I, Bogo JA, Coto-Montes A. Melatonin reduces endoplasmic reticulum stress and autophagy in liver of leptin-deficient mice. J Pineal Res. 2016;61(1):108–23.

42. Xu L, Bai Q, Rodriguez-Agudo D, Hylemon PB, Heuman DM, Pandak WM, Ren S. Regulation of hepatocyte lipid metabolism and inflammatory response by 25-hydroxycholesterol and 25-hydroxycholesterol-3-sulfate. Lipids. 2010;45(9):821–32.

43. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635–45.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit